In GEAR, ERBB2 has been annotated to enhance cell proliferation and prompt resistance of breast cancer to Letrozole, a drug is used for the treatment of hormonally-responsive breast cancer after surgery. This evidence concerns the gene ERBB2 and breast carcinoma.